Introduction {#dmw039s6}
============

In humans, the ovarian follicle is the core functional unit of the female reproductive system, which may correspond to different developmental stages in the ovary. During the female reproductive cycle, these follicles progress through a highly coordinated regulatory process that involves several neural, neuroendocrine, endocrine and paracrine/autocrine control systems to achieve full ovulatory and steroidogenic capability ([@dmw039C72]). The primary roles of the pituitary gonadotrophin hormones, FSH and LH, GnRH and the gonadal hormones (estrogen, androgen and progesterone) in the female reproductive system are well established. However, normal ovarian function and follicular development also depend on a variety of locally produced growth factors and cytokines that exert their effects in a paracrine/autocrine fashion ([@dmw039C100]). In the last few decades, studies on a variety of species have demonstrated that members of the transforming growth factor-β (TGF-β) superfamily, which include bone morphogenetic proteins (BMPs), growth differentiation factors (GDFs), TGF-βs, activins and inhibins, and anti-Müllerian hormone (AMH), are expressed in the ovary and play essential roles in the regulation of folliculogenesis, oogenesis and ovarian functions ([@dmw039C72]; [@dmw039C93]; [@dmw039C100]). With over 20 members, BMPs/GDFs constitute the largest subfamily of the TGF-β superfamily and were initially identified as osteoinductive cytokines that may promote bone and cartilage formation ([@dmw039C194]; [@dmw039C193]). Several publications have documented that locally produced BMPs are implicated in the formation and function of mammalian germ cells and that they participate in the regulation of ovarian functions ([@dmw039C207]; [@dmw039C167]; [@dmw039C98]; [@dmw039C155]). Moreover, naturally occurring gene mutations of BMP ligands and dysregulated BMP signaling are associated with prominent pathologies of human reproduction ([@dmw039C148]; [@dmw039C151]).

While the fundamental process of follicular development is highly similar across species, most information on the regulation of ovarian function is obtained from studies in rodents. Our understanding of the development and function of the human ovary has advanced only recently due to a combination of technologies including recombinant human BMPs/GDFs, immortalized human granulosa cell (GC) lines, tissue microarrays and pharmaceutical development. Thus a significant portion of this review is devoted to the human ovarian physiologies and human reproductive disorders associated with BMP/GDF signaling.

Methods {#dmw039s7}
=======

A comprehensive literature review was conducted using two databases, PubMed and Google Scholar to identify and retrieve information relevant to the field of BMP/GDF biology in the human ovary, since its initial identification in the mammalian ovary in 1999 ([@dmw039C168]) through July 2016. A systematic review of English-language publications was carried out using the following keywords: BMP, GDF, human ovary, human GCs, human GC line, female infertility and therapeutic targets. The goal of this review is to provide an overview of the current knowledge of the physiological roles of BMPs and GDFs in human female reproduction and their potential therapeutic application for regulation of fertility.

BMPs and BMP receptors {#dmw039s8}
======================

BMP ligands {#dmw039s8a}
-----------

BMPs consist of an extensive subfamily of phylogenetically conserved growth factors in the TGF-β superfamily with critical physiological functions in organogenesis and morphogenesis in both invertebrates and vertebrates ([@dmw039C81]; [@dmw039C15]). In the modern nomenclature, BMPs are regarded as encompassing growth factors that are either BMPs or GDFs due to the overlap between the two classification systems without significant separate lineages ([@dmw039C154]) (Fig. [1](#dmw039F1){ref-type="fig"}). Similar to other members of the TGF-β superfamily, BMPs are initially translated as a similar structure consisting of three components: a signal peptide, a prodomain and a mature peptide (mature domain). The signal peptide (20--30 amino acids long) is present at the N-terminal end of the newly synthesized large preproproteins, and it directs these ligands for proper secretion out of the cells ([@dmw039C190]). The BMPs share a conserved structure: the seven characteristically spaced cysteine residues indicative of the cysteine-knot motif of the TGF-β superfamily ([@dmw039C166]). Six of these cysteine residues can form intramolecular disulfide bonds known as cysteine knots, and the seventh cysteine is involved in the dimerization with another monomer via a disulfide bond to form homodimers or heterodimers ([@dmw039C176]). However, BMP15 and GDF9 are two of the few TGF-β members with only six cysteine residues in their cysteine-knot domain, each lacking the one cysteine residue responsible for covalent dimer formation ([@dmw039C123]). The inactive BMP precursors are proteolytically cleaved by a proprotein convertase family, proprotein convertase Subtilisin/Kexin, which is composed of nine members named PCSK1--PCSK9 ([@dmw039C161]). At least one member of this family, PCSK3 (furin), recognizes the amino acid motif -Arg-X-Arg/Lys-Arg- at the linker site between the prodomain and the mature domain and activates the mature BMP homodimers or heterodimers ([@dmw039C76]). Several BMP heterodimers, such as BMP2/BMP7, BMP2/BMP6, BMP4/BMP7 and BMP15/GDF9, have been suggested to exist and function both *in vivo* and *in vitro* ([@dmw039C91]; [@dmw039C113]; [@dmw039C182]; [@dmw039C145]). Most of these BMP heterodimers are more biologically potent than their respective homodimers in inducing cellular functions ([@dmw039C91]; [@dmw039C182]; [@dmw039C145]). The most likely explanation for these differential effects is that the heterodimer activity could be mediated by a different or an additional receptor subtype. Figure 1Phylogenetic relationship of the BMP/GDF subfamily members. The alignment of 21 BMP/GDF-related ligands was based on published literature: ([@dmw039C48]; [@dmw039C120]; [@dmw039C154]). Ligands with an asterisk are expressed in the human ovary. BMP/GDF, bone morphogenetic protein/growth differentiation factor.

It has been widely argued that the biological action of oocyte-derived BMP15 and GDF9 is redundant or synergistic. Evidence from a study of *Bmp15* and *Gdf9* double knockout mice demonstrated that there is a biological cooperation between these two growth factors ([@dmw039C206]). There is a great debate as to whether such cooperation results from the synergistic interaction of BMP15 and GDF9 homodimers or from the existence of a biologically active BMP15/GDF9 heterodimer ([@dmw039C132]; [@dmw039C145]; [@dmw039C148]). Interestingly, the BMP15/GDF9 heterodimer can be produced and secreted in 293 T cells (a specific cell line originally derived from human embryonic kidney cells) when two constructs are co-expressed ([@dmw039C109]). Indeed, the human BMP15/GDF9 heterodimer is approximately 1000- to 3000-fold more potent than the human BMP15 homodimer ([@dmw039C145]).

BMP receptors {#dmw039s8b}
-------------

TGF-β superfamily members signal through distinct sets of transmembrane serine/threonine kinase receptors (type I and type II receptors), which further regulate downstream gene expression by phosphorylating the Sma- and Mad-related protein (SMAD) transcription factors ([@dmw039C166]). To date, five distinct type II receptors (BMPR2, ACVR2A, ACVR2B, TβR2 and AMHR2) and seven type I receptors (also known as activin receptor like-kinase; ALK1--7) have been identified in mammals ([@dmw039C119]; [@dmw039C128]). All of these receptors share a very similar structure consisting of an extracellular domain (N-terminal), a transmembrane domain and an intracellular domain with Ser/Thr kinase activity (C-terminal). Each ligand of the TGF-β superfamily members can bind to the N-terminal extracellular domains of different combinations of type II and type I receptors and trigger downstream signaling complexes ([@dmw039C119]; [@dmw039C128]). Of the five type I receptors, three (BMPR2, ACVR2A and ACVR2B) are employed by one or more BMPs. Likewise, six (ALK2-7) of the seven type I receptors have been implicated in BMP-induced intracellular signaling ([@dmw039C115]; [@dmw039C95]; [@dmw039C130]; [@dmw039C120]; [@dmw039C127]). Receptors and signaling pathways utilized for various intra-ovarian BMPs/GDFs in human cells are listed in Table [I](#dmw039TB1){ref-type="table"}. Table IPutative receptors and signaling pathways of BMPs/GDFs in the human ovary.LigandType II receptorType I receptorSMADReferencesBMP2BMPR2, ACVR2AALK3/6SMAD1/5/8[@dmw039C120]BMP4BMPR2, ACVR2AALK3/6SMAD1/5/8[@dmw039C127][@dmw039C22], [@dmw039C25]ALK3/4/5SMAD2/3[@dmw039C210]BMP6BMPR2, ACVR2AALK2/3/6SMAD1/5/8[@dmw039C120]BMP7BMPR2, ACVR2AALK2/3/6SMAD1/5/8[@dmw039C115][@dmw039C22], [@dmw039C23], [@dmw039C25]BMP15BMPR2ALK3/6SMAD1/5/8[@dmw039C130][@dmw039C24]GDF8ACVR2A, ACVR2BALK5SMAD2/3[@dmw039C30][@dmw039C28], [@dmw039C31], [@dmw039C32]GDF9BMPR2ALK5SMAD2/3[@dmw039C120][@dmw039C95][^1]

BMP signaling {#dmw039s8c}
-------------

Members of the TGF-β superfamily exert their functions by binding to type I and type II receptors, which further regulate downstream target gene expression by phosphorylating the receptor-regulatory SMAD (R-SMAD) transcription factors, SMAD1--8. Generally, two distinct models of the ligand--receptor interaction exist. BMPs, AMH and some GDFs activate SMAD1/5/8 via ALK2, ALK3 and/or ALK6; whereas, TGF-βs, activins and nodal activate SMAD2/3 via ALK4, ALK5 and/or ALK7 ([@dmw039C47]; [@dmw039C133]). Upon phosphorylation of type I receptors, BMPs activate the canonical SMAD1/5/8 group, which then associate with the common SMAD (SMAD4), and this complex translocates to the nucleus to exert functions that regulate gene expression in most tissues.

Quite recently, novel non-canonical SMAD2/3 signaling (commonly induced by TGF-βs and activins) activated by BMPs to regulate cancer progression and hormone production has been given considerable attention ([@dmw039C82]; [@dmw039C196]). In human granulosa tumor cells and mouse GCs, recombinant human BMP15, but not mouse BMP15, mildly phosphorylated SMAD2/3 and stimulated mouse cumulus--oocyte complex (COC) expansion ([@dmw039C145]). In line with these reports challenging the standard guideline that BMPs exert cellular functions solitarily through canonical SMAD1/5/8 signaling, our most recent studies showed that BMPs-induced *hyaluronan synthase type 2* (*HAS2*) expression is mediated by noncanonical SMAD2/3 signaling through binding to ALK4/5/7 in immortalized human GCs ([@dmw039C210]). Differences in receptor expression levels and receptor binding properties between different BMPs (homodimers or heterodimers) most likely contribute to the differential activation of noncanonical SMAD2/3 signaling in certain cell types.

In addition to the SMAD signaling, several SMAD-independent (non-SMAD) signaling pathways for BMPs have been identified in specific tissues. It is widely believed that the mitogen-activated protein kinase (MAPK) signal pathway is the major SMAD-independent pathway induced by BMPs. BMP4 has been found to phosphorylate TGF-β activated kinase 1, a serine/threonine kinase of the MAPKKK family ([@dmw039C204]; [@dmw039C41]). Previous studies indicate that BMPs are also able to activate several signaling pathways, including phosphoinositide 3-kinase, extracellular signal-regulated kinase (ERK), protein kinase (PK) A, PKC and PKD (PKCμ) ([@dmw039C204]; [@dmw039C135]; [@dmw039C192]). Interestingly, our recent study showed that the BMP subfamily member GDF8 decreases steroidogenic acute regulatory protein (StAR) expression by activating both the SMAD3 and ERK signaling pathways ([@dmw039C55]). Upon ligand--receptor binding and interaction, the subsequent pathway activated by BMPs is most likely dependent on other cellular activity, the extracellular environment and crosstalk with other signaling pathways.

Intra-ovarian BMPs and oocyte--somatic cell interactions {#dmw039s9}
========================================================

Human GC lines {#dmw039s9a}
--------------

To clearly understand the underlying mechanisms by which hormones or growth factors regulate folliculogenesis and ovarian steroidogenesis, available cell models that are suitable for *in vitro* studies are warranted. GC-based *in vitro* cell model systems have provided valuable tools for studying ovarian biology. The major source of human GCs for *in vitro* studies is usually from infertile patients undergoing IVF. However, these cells are obtainable only in small numbers, which make it difficult to conduct extensive experiments related to detailed molecular analysis. In addition, the clinically obtained GCs are generally luteinized because of their extensive stimulation with FSH/LH and hCG prior to cell isolation. Therefore, these GCs have a limited life span with a slow proliferation rate, and they do not survive *in vitro* for many passages ([@dmw039C17]). Furthermore, primary GCs derived from different patients may exhibit wide variability, which adds to the difficulty of obtaining reproducible results. Because of these obstacles, a substitute human GC line has become an attractive option. In the last few years, there has been a growing interest in developing several cell lines from human GCs (Table [II](#dmw039TB2){ref-type="table"}). These cell lines were generated through various techniques, including oncogenic transformation ([@dmw039C152]; [@dmw039C110]; [@dmw039C83]; [@dmw039C140]; [@dmw039C177]; [@dmw039C141]), transfection with site-directed mutagenesis ([@dmw039C13]) and explants of human tumors ([@dmw039C89]; [@dmw039C183]; [@dmw039C138]). Notably, each cell line may have different cell properties with regard to steroidogenic functions, gonadotrophin (FSH and LH) responsiveness, cAMP responsiveness, BMP responsiveness, and mitogenic and differential capabilities ([@dmw039C77]) (Table [II](#dmw039TB2){ref-type="table"}). Therefore, it is essential to choose the appropriate cell line for individual studies. For instance, the SVOG cell line was developed by transfection of human granulosa-lutein (hGL) cells using SV40 large T antigen ([@dmw039C110]) (Table [II](#dmw039TB2){ref-type="table"}). Primary hGL cells were used to generate the immortalized cells and the two display similar biological responses to many different treatments, such as LH, hCG, cAMP and various growth factors ([@dmw039C110]). As demonstrated in numerous previous publications from our laboratory as well as those of other investigators, these cells are a widely accepted model to study the ovarian response during the periovulatory and early luteal phases ([@dmw039C77]; [@dmw039C22], [@dmw039C25], [@dmw039C32], [@dmw039C28]; [@dmw039C58]). COV434 and KGN are two widely used GC lines originating from ovarian GC tumors ([@dmw039C183]; [@dmw039C211]; [@dmw039C138]). Unfortunately, the development of an androgen-producing thecal cell line has faced a tough challenge with limited success ([@dmw039C116]; [@dmw039C121]). Table IIThe cellular properties of human ovarian GC lines.Cell lineOriginTransfectionProgesterone productionAromatase activitySteroidogenic enzymeFSH responseLH/hCG responsecAMP responseBMP responseReferencesSVOGLuteinized GCSV40 T(+)(−)(+)(−)(+)(+)(+)[@dmw039C110]HGL5Luteinized GCHPV16E6/E7(+)(+)(+)(−)(−)(+)(+)[@dmw039C152]HO-23Luteinized GCSV40 T, Ha-ras p53(+)ND(+)ND(−)(+)ND[@dmw039C83]HGP53Luteinized GCHa-ras & p53val135(+)ND(+)(+)ND(+)ND[@dmw039C178]GC1aNon-luteinized GCMouse SF-1(−)(−)(−)(−)(−)NDND[@dmw039C140][@dmw039C141]HGrC1Non-luteinized GCHPV16E6/E7, CDK4R24C, cyclin D1(+)(+)(+)(+)(+)ND(+)[@dmw039C13]COV434Metastatic GC tumor(+)(+)(−)(+)(−)(+)(+)[@dmw039C183]KGNGC carcinoma(+)(+)(−)(+)(−)(+)(+)[@dmw039C138]HTOGGranulosa-theca cell tumor(+)(+)NDNDNDNDND[@dmw039C89][^2]

Expression of BMPs and BMP receptors in the human ovary {#dmw039s9b}
-------------------------------------------------------

A number of studies performed over the past decade have provided important information about the expression of the BMP system in the mammalian ovary, with the most comprehensive study using adult cycling rats ([@dmw039C54]; [@dmw039C167]). However, the expression pattern of BMPs in the rat ovary may not necessarily apply to other species. For instance, BMP4 and BMP7 are primarily expressed by theca and stroma cells in rats ([@dmw039C54]); however, both BMP4 and BMP7 have been detected in human oocytes ([@dmw039C2]). GDF9 has been identified in hGL cells and oocytes ([@dmw039C1]; [@dmw039C179]; [@dmw039C85]; [@dmw039C163]), but GDF9 is exclusively expressed in the oocytes of ovine and bovine ovaries ([@dmw039C16]; [@dmw039C79]). Likewise, BMP15, which was previously thought to be oocyte-derived ([@dmw039C1]), has been detected in human cumulus cells ([@dmw039C108]), GCs and stroma cells in girls and adults ([@dmw039C118]). The development and physiological functions of the human reproductive system are mostly influenced by the tissue-specific and time-dependent expression of BMP subfamily members ([@dmw039C167]), even though the spatiotemporal expression pattern of BMPs in the human ovary remains largely unknown. The expression of BMP/GDF ligands and their receptors in human ovarian tissues is listed in Table [III](#dmw039TB3){ref-type="table"}. In the human ovary, BMP2, BMP4, BMP5, BMP6, BMP7 and BMP8A are expressed in the GCs from normally cycling and polycystic ovary syndrome (PCOS) women ([@dmw039C97]). In concert with this study, a study using isolated human pre-antral follicles that compared the expression levels of BMPs in five size-matched populations demonstrated that BMP6 and BMP15 are the most abundantly expressed ligands ([@dmw039C102]). In the human corpus luteum, BMP2, BMP4 and BMP6 are highly expressed in the granulosa-lutein and theca-lutein cells and are involved in the process of luteolysis ([@dmw039C137]). Table IIILocalization of BMPs/GDFs and receptors in the human ovary.LigandsLocalizationExpressionDetection methodReferencesBMP2Luteinized GCmRNART-qPCR[@dmw039C97]CLmRNART-qPCR[@dmw039C137]FF (1--115 ng/ml)ProteinELISA[@dmw039C175]BMP4Luteinized GCmRNA & ProteinRT-qPCR, IHC[@dmw039C97]Oocyte^[a](#dmw039tfn3){ref-type="table-fn"}^ProteinIHC[@dmw039C2]Theca/stroma cells^[a](#dmw039tfn3){ref-type="table-fn"}^ProteinIHC[@dmw039C2]GC^[a](#dmw039tfn3){ref-type="table-fn"}^ProteinIHC[@dmw039C2]CLmRNA & ProteinRT-qPCR, IHC[@dmw039C137]FF (1--20 pg/ml)ProteinELISA[@dmw039C22]BMP5Luteinized GCmRNART-qPCR[@dmw039C97]BMP6Luteinized GCmRNA & ProteinRT-qPCR, IHC[@dmw039C97]CLmRNA & ProteinRT-qPCR, IHC[@dmw039C137]BMP7Luteinized GCmRNA & ProteinRT-qPCR, IHC[@dmw039C97]OocyteProteinIHC[@dmw039C2]Theca/stroma cellsProteinIHC[@dmw039C2]GCProteinIHC[@dmw039C2]FF (50--130 ng/ml)ProteinELISA[@dmw039C175]BMP8ALuteinized GCmRNART-qPCR[@dmw039C97]BMP15Pre-antral follicles (\>75 μm)mRNATissue microarray[@dmw039C102]Cumulus cellsmRNART-qPCR[@dmw039C108]OocytemRNA & Protein*In situ* hybridization, RT-qPCR, IHC[@dmw039C118][@dmw039C1][@dmw039C179]Theca/stroma cellsmRNA & Protein*In situ* hybridization, IHC[@dmw039C118]GCmRNA & Protein*In situ* hybridization, IHC[@dmw039C118]FFProteinWestern blot[@dmw039C203]GDF8Luteinized GCmRNART-qPCR[@dmw039C30]FF (2.01--4.17 ng/ml)ProteinELISA[@dmw039C30]GDF9Pre-antral folliclesmRNATissue microarray[@dmw039C102]Cumulus cellsmRNART-qPCR[@dmw039C108]OocytemRNA & Protein*In situ* hybridization, IHC[@dmw039C1][@dmw039C179]Luteinized GCmRNA & ProteinRT-PCR, Western blot[@dmw039C85]FF (0.83--53.9 ng/ml)ProteinELISAALK2Luteinized GCmRNART-qPCR[@dmw039C97]ALK3Luteinized GCmRNA & ProteinRT-qPCR, IHC[@dmw039C97]GCProteinIHC[@dmw039C2]OocyteProteinIHC[@dmw039C2]CLmRNA & ProteinRT-qPCR, IHC[@dmw039C137]ALK5Luteinized GCmRNART-qPCR[@dmw039C97]ALK6Luteinized GCmRNA & ProteinRT-qPCR, IHC[@dmw039C97]OocyteProteinIHC[@dmw039C2]Stroma cellsProteinIHC[@dmw039C2]GCProteinIHC[@dmw039C2]CLmRNA & ProteinRT-qPCR, IHC[@dmw039C137]BMPR2Luteinized GCmRNA & ProteinRT-qPCR, IHC[@dmw039C97]OocyteProteinIHC[@dmw039C2]Stroma cellsProteinIHC[@dmw039C2]GCProteinIHC[@dmw039C2]CLmRNA & ProteinRT-qPCR, IHC[@dmw039C137][^3][^4]

During the antral follicular stage, the growth and maturation of the oocyte are dependent on several intra-ovarian factors present in the follicular fluid ([@dmw039C84]). The concentrations of some of the follicular fluid growth factors are correlated with the serum levels of these factors ([@dmw039C150]). The imbalance of any of these intra-ovarian factors may lead to abnormal follicular development and dysfunction of oocyte maturation in humans ([@dmw039C62]; [@dmw039C150]). Recent studies have shown that BMP2, BMP4, BMP7, BMP15, GDF8 and GDF9 are detectable in the follicular fluid (Table [III](#dmw039TB3){ref-type="table"}) ([@dmw039C175]; [@dmw039C203]; [@dmw039C22]; [@dmw039C30]). Among these follicular fluid BMPs, the results from clinical data suggested that BMP2 and BMP15 may potentially be used as indicators of oocyte fertilization and/or oocyte maturation ([@dmw039C202]; [@dmw039C175]).

Previous research has documented the expression of the mRNA and protein of BMP receptors in various follicular compartments of pre-antral and antral follicles of the human ovary ([@dmw039C97]; [@dmw039C102]). Among these receptors, BMPR2 is the most abundantly expressed type II receptor ([@dmw039C102]). In comparison with the type I receptors ALK1, ALK2 and ALK7, four type I receptors ALK3, ALK4, ALK5 and ALK6 are expressed at modest levels in the human pre-antral follicles ([@dmw039C102]). A recent study showed that the dysregulation of ALK6 in human GCs is associated with reduced ovarian reserve and the age-related decline in fertility ([@dmw039C153]).

BMPs and primordial germ cell development {#dmw039s9c}
-----------------------------------------

Primordial germ cells (PGCs), the precursors of the sperm and egg in the adult, are a group of germline stem cells that develop only during the early embryonic stage ([@dmw039C124]). These stem cells migrate to the primitive gonadal fold and mitotically proliferate to increase cell numbers, which subsequently differentiate into primordial follicles (oocytes associate with the surrounding somatic cells) ([@dmw039C146]). Members of the BMP subfamily play critical roles in regulating ovarian development and function ([@dmw039C167]; [@dmw039C100]). However, the developmental processes are differentially regulated in rodents and humans with respect to the spatiotemporal organization ([@dmw039C105]; [@dmw039C36]). In mouse embryos, the extraembryonic ectoderm-derived BMP4 and BMP8B collaboratively induce PGC formation ([@dmw039C208]). In human fetal ovaries, BMP4 and BMP signaling modulates post-migratory PGC numbers by promoting apoptosis ([@dmw039C36]). During oogenesis in humans, GDF9 is transiently secreted by oocytes before follicle formation, which is accompanied by activin βA signaling from somatic cells to determine selective germ cell survival ([@dmw039C14]). Figure 2Schematic diagram summarizing functional roles of BMPs and GDF9 in the human ovary. The potential physiological roles of intra-ovarian BMPs in regulating human ovarian functions, including steroidogenesis, activin production, cumulus--oophorus complex formation and expansion, cell--cell communication, ovulation and luteolysis are shown. BMP, bone morphogenetic protein; COC, cumulus--oophorus complex; Cx43, connexin 43; GC, granulosa cell; HAS2, hyaluronan synthase type 2; PTX3, pentraxin 3; StAR, steroidogenic acute regulatory protein.

BMPs and intra-ovarian cell--cell communication {#dmw039s9d}
-----------------------------------------------

The ovarian follicle is the principal functional unit of the female reproductive system. A coordinated interplay within this biological compartment between the oocyte and the follicular cells (cumulus cells/GCs and theca/stroma cells) depends heavily on functional gap junctions ([@dmw039C73]). These connexin-coupled cell junctions directly mediate cell--cell communication by allowing the passage of small molecules (ions, metabolites, nutrition and small signaling molecules) between two adjacent cells ([@dmw039C20]; [@dmw039C117]). In the growing follicles in humans, connexin 43 (Cx43) primarily contributes to the formation of gap junctions between cumulus cells/GCs, whereas gap junctions that connect the oocyte to the surrounding cumulus cells are mainly composed of connexin 37 (Cx37) ([@dmw039C63]; [@dmw039C181]; [@dmw039C66]). Studies in knockout mice demonstrated that mice lacking *Cx43* exhibit a phenotype of reduced germ cell numbers in the fetal gonads, retarded growth of oocytes and fertilization failure ([@dmw039C4]). In addition, the ablation of *Cx37* leads to an abolition of intercellular coupling between oocytes and cumulus cells, disruption of follicle development at the antral stage, incompetent oocytes and ovulatory dysfunction ([@dmw039C169]).

Cx43 is abundantly expressed in the GCs throughout all follicular stages and its expression is required for GC proliferation ([@dmw039C4]; [@dmw039C70]). The cyclic expression of Cx43 in the GCs is developmentally and hormonally regulated by gonadotrophins (FSH and LH) and steroid hormones (estrogen, progesterone and androgen) in many species, including humans ([@dmw039C149]; [@dmw039C73]; [@dmw039C201]). Our recent studies have shown that three intra-ovarian BMPs (BMP4, BMP7 and BMP15) and TGF-β1 may act in a paracrine/autocrine manner to modulate *Cx43* expression and intercellular communication in human GCs (Fig. [2](#dmw039F2){ref-type="fig"}) ([@dmw039C27], [@dmw039C29], [@dmw039C35]). Specifically, BMP-mediated signaling suppresses *Cx43* expression, whereas TGF-β1 increases *Cx43* expression, indicating competing regulatory roles for these paracrine/autocrine factors. This functional discrepancy between the growth factors belonging to the TGF-β superfamily of differential signaling molecules (TGF-βs and BMPs) may influence a broad range of cellular actions.

Oocyte-somatic cell interactions {#dmw039s9e}
--------------------------------

In the mammalian ovary, oocytes do not merely reside inside the follicles and passively receive the developmental signals from the surrounding cumulus cells/GCs, but they actively govern and modulate follicular development and ovulation. Within the follicular microenvironment, oocytes and the supporting somatic cells coordinately control the development and maturation of the follicle as well as the acquisition of a meiotically competent oocyte ([@dmw039C52]). The results obtained from animal studies indicated that oocytes might promote follicular development and cell differentiation by releasing some growth factors that act in a paracrine manner to affect the neighboring cumulus cells/GCs. These paracrine effects, in turn, modulate oocyte development and maturation ([@dmw039C52]). Studies in sheep and mice have shown that the experimental ablation (removal, absence or destruction) of the oocytes results in impaired folliculogenesis, indicating a critical role of the oocyte factors or oocyte-induced paracrine signaling in follicular development ([@dmw039C136]; [@dmw039C69]). An *in vivo* study has revealed that ovectomy can lead to the spontaneous transformation of the Graafian follicle into the corresponding corpus luteum ([@dmw039C49]). *In vitro* experiments have demonstrated that oocyte-secreted factors may potently promote DNA synthesis and cell proliferation in the surrounding cumulus/mural GCs ([@dmw039C187]; [@dmw039C68]). In addition, these oocyte-derived potent mitogens can also augment the effects of several GC regulators (FSH, insulin-like growth factor-I and androgen) on cell growth activities ([@dmw039C7]; [@dmw039C61]; [@dmw039C107]; [@dmw039C80]).

Aside from the mitogenic effects, oocytes are potent modulators of cumulus cell/GC differentiation in various species, including humans ([@dmw039C52]). In particular, oocytes modulate the FSH-stimulated estradiol and progesterone production by GCs ([@dmw039C185]; [@dmw039C39]; [@dmw039C188]), whereas they suppress the expression of LH receptor (LHR) induced by FSH in GCs ([@dmw039C53]). Apart from the gonadotrophins secreted by the pituitary gland, oocyte-derived BMP15 and GDF9 also participate in the modulation of certain target genes related to ovulation and luteinization ([@dmw039C143]; [@dmw039C44]). In human GCs, oocyte-derived BMP15 decreases progesterone production by down-regulating the expression of *StAR* ([@dmw039C29]). Collectively, these results support a previously proposed hypothesis that the oocyte is capable of inhibiting follicular luteinization (Fig. [2](#dmw039F2){ref-type="fig"}) ([@dmw039C49]).

Data collected from the cumulus cell transcriptome revealed that bi-directional communication between the human oocyte and cumulus cells is essential for the production of a competent oocyte ([@dmw039C87]). In this regard, the oocyte acts as a central regulator of neighboring follicular cell function by secreting various growth factors and cytokines to modulate cell proliferation, cell differentiation, apoptosis and luteinization ([@dmw039C67]). At ovulation, cumulus expansion is a complicated process that is required for the optimal extrusion of the cumulus--oocyte cell mass from the follicle ([@dmw039C156]). The cumulus expansion process and oocyte maturation are highly dependent on the interactions of two signals induced by epidermal growth factor (EGF)-like peptides (triggered by LH or hCG) and an oocyte-derived paracrine factor ([@dmw039C84]; [@dmw039C56]). Specifically, the oocyte-derived factor capacitates the response of cumulus cells to three EGF-like peptides, which induces the expression of several target genes \[*HAS2*, *tumor necrosis factor alpha-induced protein 6 (TNFAIP6)*, pentraxin 3 (*PTX3)* and *prostaglandin-endoperoxide synthase 2 (PTGS2)*\] related to extracellular matrix formation and stability ([@dmw039C44]). Indeed, the *in vitro* studies have shown that oocyte factors, GDF9 and, to a lesser extent, BMP4 and BMP7 induce *HAS2* expression and hyaluronan synthesis as well as prostaglandin E~2~ production, which is essential for normal ovulation ([@dmw039C50]; [@dmw039C210]). The knowledge obtained from cumulus--oocyte interactions during the periovulatory stage will enable clinicians to design optimal procedures for ART, especially the IVM protocol.

BMPs prevent premature luteinization {#dmw039s9f}
------------------------------------

In humans, the LH surge stimulates multiple intra-follicular activities and triggers ovulation ([@dmw039C156]). At the time of ovulation, a series of morphological transitions and tissue remodeling cause the ruptured ovarian follicle to develop into the corpus luteum, a temporary endocrine structure that secretes progesterone ([@dmw039C142]). The release of progesterone targets and prepares the reproductive tract for initiation of fertilization and maintenance of early pregnancy ([@dmw039C139]). Premature luteinization refers to an elevation of serum progesterone levels on (or before) the day of hCG administration in patients undergoing controlled ovarian stimulation ([@dmw039C5]). The premature rise of progesterone can shift the implantation window (synchronization between embryonic development and endometrial receptivity), which may hamper embryo implantation and decrease the pregnancy rate ([@dmw039C3]). During the antral follicle stage, one of the most important physiological functions is the prevention of premature luteinization, which maintains follicular growth and somatic cell proliferation ([@dmw039C10]).

Evidence from animal studies has shown that the regulation of steroid hormones by BMPs is species- and stage-specific in the pre-antral and antral follicular stages. In humans, some inconsistent results have been published regarding the regulatory effects of BMPs on ovarian steroid hormone synthesis. In a human granulosa tumor cell line (KGN), BMP4 and BMP7 suppressed forskolin- or cAMP-induced progesterone production without affecting forskolin- or cAMP-induced estradiol production ([@dmw039C129]). In contrast, a cohort study using GCs from normal healthy women and PCOS women showed that BMP7, but not BMP4, suppressed basal estradiol production, and both BMP4 and BMP7 had no effect on FSH-induced estradiol production in the normal women ([@dmw039C97]). Studies using primary GCs obtained from IVF patients showed that BMP2, BMP4 and BMP6 suppressed *StAR* expression, whereas BMP2 induced aromatase expression ([@dmw039C165]; [@dmw039C137]). Consistent with some of the previous studies, our recent results showed that BMP4, BMP7 and BMP15 all decreased progesterone production by down-regulating ALK3-mediated *StAR* expression in immortalized GCs (SVOG cells), but not in KGN cells ([@dmw039C27]; [@dmw039C209]). Moreover, BMP4 and BMP7 increased the synthesis of bioactive activin A by up-regulating the production and proteolytical processing of the inhibin βA subunit in human immortalized GCs ([@dmw039C25]). Activin A is another potent luteinization inhibitor because of its ability to decrease the basal and FSH- or LH-induced progesterone production in hGL cells ([@dmw039C26]). GDF9, a close relative of BMP15, has divergent roles in the regulation of human steroid production. In human GCs and theca cells, GDF9 suppresses 8-bromo-cAMP-induced StAR expression and progesterone production without affecting basal StAR protein levels or progesterone production ([@dmw039C205]; [@dmw039C164]).

Taken together, all of these studies in the human follicle cells suggest that the secretion of BMPs from oocytes, GCs or theca/stroma cells inhibits StAR expression and, in turn, decreases progesterone production. On the other hand, oocyte-derived GDF9 interacts with pituitary gonadotrophins to further reduce progesterone production (Fig. [2](#dmw039F2){ref-type="fig"}). After ovulation, the dramatic decrease in GDF9 and BMP15 levels in the corpus luteum leads to elevated StAR expression and a subsequent increase in progesterone production.

BMPs modulate COC formation and expansion {#dmw039s9g}
-----------------------------------------

During the antral follicle stage (characterized by the formation of a fluid-filled antrum), the original GCs that surround the oocyte differentiate into two functionally and anatomically distinct sublineages, the cumulus cells and mural GCs. The cumulus cells intimately interact with the oocyte to form an elaborate structure called the COC, while mural GCs are layered against the follicle wall and close to the basement membrane and theca/stroma cells ([@dmw039C6]). During the periovulatory stage, these two types of GC exhibit highly divergent characteristics. In general, cumulus cells are enriched for transcripts involved in cell proliferation and metabolism, whereas mural GCs are enriched for transcripts associated with cell differentiation and signaling ([@dmw039C199]). In contrast to mural GCs, cumulus cells display a higher cell proliferation rate, a higher AMH expression level, a lower steroidogenic capacity, a lower LHR expression level and have the ability to secrete hyaluronic acid for COC expansion (cumulus expansion) ([@dmw039C7]; [@dmw039C53]; [@dmw039C107]; [@dmw039C74]). The cumulus cells associate with the oocyte and the extended viscoelastic extracellular matrix to form a unique structure, the hyaluronan-rich COC matrix ([@dmw039C156]). Hyaluronan is the structural backbone of this matrix, which is further stabilized by a complex network of binding proteins, including versican, tumor necrosis factor-stimulated gene 6 protein (TSG-6), inter-α trypsin inhibitor and PTX3 ([@dmw039C157]; [@dmw039C12]).

At mid-cycle, the LH surge initiates the ovulatory process by decreasing cell--cell communication, resuming oocyte meiotic maturation, generating tissue remodeling and inducing the expansion of the COC ([@dmw039C156]). The cumulus expansion, characterized by a process of morphological change involved in the proliferation and dispersion of cumulus cells, is initiated under the control of several endocrine, paracrine and oocyte-derived factors ([@dmw039C51]; [@dmw039C189]; [@dmw039C156]; [@dmw039C56]). *In vitro* studies have demonstrated the requirement of either the oocyte or its conditioned medium for the response of cumulus cells to EGF, FSH or cAMP in the synthesis of hyaluronan ([@dmw039C18]; [@dmw039C158]). In cumulus cells, the key enzyme responsible for the polymerization and elongation of the hyaluronan chains to localize into the intercellular space is a transmembrane protein, HAS2 ([@dmw039C198]). Indeed, the human BMP15 homodimer and mouse GDF9 are able to up-regulate the cumulus expansion-related genes (*Has2*, *Ptx3* and *Ptgs2*) in mouse GCs and promote cumulus expansion *in vitro* ([@dmw039C145]).

In the structure of the hyaluronan-based extracellular matrix, PTX3 plays a critical role in the assembly process. In this stable and sustainable hyaluronan network, PTX3 acts as an aggregating reagent to link to a molecule, TSG-6, which is further bound to the distinct hyaluronan strand ([@dmw039C12]). The knockout mouse model has been used to highlight the essential roles of PTX3 and cumulus expansion in the processes of oocyte maturation and ovulation, efficient transportation of the oocyte through the oviducts and *in vivo* fertilization ([@dmw039C186]). Mice lacking *Ptx3* display subfertility, structural defects of the COC and failed *in vivo* fertilization ([@dmw039C189]). Our recent study showed that BMP4 and BMP7 down-regulated the expression and protein production of PTX3 in human GCs, indicating that BMPs may participate in extracellular matrix formation and tissue remodeling. Collectively, we can speculate that oocyte-secreted factors (mainly BMP15 and GDF9) maintain the cumulus cell phenotype by promoting cumulus expansion, whereas theca/stroma-derived BMPs (mainly BMP4 and BMP7) decompose the structure of the extracellular matrix in the neighboring mural GCs to facilitate the separation of COC and mural GCs in the human ovary (Fig. [2](#dmw039F2){ref-type="fig"}).

BMPs and luteal function {#dmw039s9h}
------------------------

In the absence of pregnancy, the corpus luteum begins to regress at the end of the luteal phase, a degradation process called luteolysis ([@dmw039C88]). Luteolysis is a complicated process involving a loss of the structural and functional integrity of the corpus luteum accompanied by a decrease in progesterone production ([@dmw039C88]). Studies using human ovarian tissues demonstrated that the expression levels of BMP2, BMP4 and BMP6 are increased during luteal regression and they are differentially regulated by hCG, suggesting that these BMPs may be involved in the process of luteolysis ([@dmw039C137]) (Fig. [2](#dmw039F2){ref-type="fig"}).

Role of BMPs in female reproductive pathology {#dmw039s10}
=============================================

Any abnormality in the intra-ovarian BMPs or BMP signaling may negatively affect oocyte--somatic cell interactions, steroidogenesis, GC proliferation, oocyte maturation, cumulus expansion, ovulation, embryonic quality and luteal function, leading to female infertility and reproductive pathology. Knocking out of *Bmp4* or the depletion of *Alk2* in mouse embryos results in a lack of PGC formation ([@dmw039C105]). Genetic depletion of the *Bmp6* gene in female mice causes a decrease in number of ovulated eggs and reduced litter size ([@dmw039C174]). Oocyte-derived BMP15 and GDF9 are the prominent BMP/GDF associated with various ovarian functions and ovulation rate ([@dmw039C148]). Abnormal expression of these two factors may be related to female infertility ([@dmw039C67]). The results from clinical data have suggested that BMP15 levels in the follicular fluid may be used as an indicator of oocyte quality and subsequent fertilization ability ([@dmw039C202]). In addition, a couple of BMP receptors have been shown to be involved in implantation and maternal--fetal interactions during human pregnancy. Disruption of BMPR2-mediated signaling in the uterine decidua leads to placental abruption, fetal demise and female sterility ([@dmw039C134]). During mouse pregnancy, mice carrying a conditional ablation of *Alk2* in the uterus (*Alk2* cKO mice) exhibit delayed embryo invasion into the uterine stroma, failed uterine decidualization and sterility. Likewise, ablation of *ALK2* using siRNA targeted to *ALK2* in human uterine stromal cells may alter uterine decidualization and embryo implantation, leading to female sterility ([@dmw039C37]).

Polycystic ovary syndrome {#dmw039s10a}
-------------------------

Using immunohistochemical staining, the expression levels of BMP15 and GDF9 proteins in the oocyte and GCs of follicles in PCOS ovaries are reduced and delayed during the early follicular stage ([@dmw039C197]). Compared with the control group, the expression levels of BMP15 and GDF9 proteins in the oocytes tended to be higher in women with PCOS, which could be the result of PCOS follicular dysplasia ([@dmw039C213]). However, the expression levels of GDF9 protein in cumulus cells are lower in PCOS women, which may result in premature luteinization, poor oocyte competence and luteal dysfunction, leading to higher miscarriage rates in PCOS patients ([@dmw039C213]). These results provide evidence of two valuable intra-ovarian growth factors in the regulation of oocyte maturation in the follicular microenvironment and will help in the design of a potential technique to improve IVM protocols for oocytes from women with PCOS ([@dmw039C150]). Most serum BMP protein levels are either undetectable or at the lower limit of detection in PCOS women, and therefore provide limited information about this disease ([@dmw039C184]). The data generated from genome-wide association studies indicate that the involvement of *BMP15* or *GDF9* genetic variations in the etiology of PCOS remains controversial ([@dmw039C178]; [@dmw039C71]; [@dmw039C114]; [@dmw039C148]).

Primary ovarian insufficiency {#dmw039s10b}
-----------------------------

Several *BMP15* gene mutations have been reported in primary ovarian insufficiency (POI) patients with primary or secondary amenorrhea ([@dmw039C178]; [@dmw039C42], [@dmw039C43]; [@dmw039C21]; [@dmw039C46]; [@dmw039C147]; [@dmw039C180]; [@dmw039C9]; [@dmw039C59]). The first missense mutation in the *BMP15* gene was identified in two Italian sisters with familial ovarian dysgenesis and primary amenorrhea ([@dmw039C42]). Compared to the normal human BMP15 protein, a recombinant BMP15 developed from this mutant gene fails to stimulate GC growth activity and is unable to inhibit progesterone production in primary human GCs ([@dmw039C9]). Like *BMP15*, several cohort studies involving different populations with POI have been conducted to screen for *GDF9* gene mutations ([@dmw039C45]; [@dmw039C104]; [@dmw039C101]; [@dmw039C195]; [@dmw039C170]). However, various missense mutations encoding different GDF9 mutant proteins may display contrasting results in functional studies. Some variants significantly decrease mature GDF9 protein production and diminish the ability of GDF9 to stimulate GC proliferation ([@dmw039C195]). In contrast, other variants may encode a mutant GDF9 that significantly increases GC proliferation ([@dmw039C170]).

Endometriosis {#dmw039s10c}
-------------

Endometriosis is defined as the presence of endometrial tissue outside the uterine cavity, which affects 10% of reproductive-aged women ([@dmw039C191]). Although many theories have been proposed, the precise pathogenesis and molecular mechanism of this common disease remain unknown ([@dmw039C19]). Immunohistochemical staining of endometriotic lesions obtained from 85 patients revealed that BMP6 is strongly expressed in both the epithelial and stromal cells ([@dmw039C8]). A genome-wide profiling analysis comparing the gene expression of ectopic and eutopic endometrial tissues showed that BMP4 and its antagonist, GREM1, are dysregulated in endometriosis ([@dmw039C40]). Future studies aimed at addressing the functional roles of BMPs in the development of endometriosis will be of great interest.

Novel role of GDF8 in the human ovary {#dmw039s11}
=====================================

Originally identified in the musculoskeletal system, GDF8 is one of the members of the TGF-β superfamily ([@dmw039C125]). GDF8 and BMP11 (GDF11) are two closely related growth factors that share a similar structure and function ([@dmw039C64]). Also known as myostatin, GDF8 is a potent inhibitor of skeletal muscle growth and development ([@dmw039C125]). Mice carrying a targeted mutation of the *Gdf8* gene have an \~25--30% increase in muscle mass because of muscle fiber hypertrophy and hyperplasia ([@dmw039C125]). Naturally occurring *GDF8* gene mutations leading to increased muscle mass have been reported in several species, including cattle, sheep, dogs and humans ([@dmw039C126]; [@dmw039C160]; [@dmw039C38]; [@dmw039C131]). In the last few years, there has been a growing interest in the investigation of GDF8's functional roles outside of the musculoskeletal systems. Notably, the expression and potential functions of GDF8 have recently been investigated in several reproductive organs, including the uterus and placenta ([@dmw039C90]; [@dmw039C144]). Furthermore, data from clinical samples have highlighted the possible involvement of GDF8 in the pathogenesis of certain reproductive disorders, such as uterine myoma, pre-eclampsia and PCOS ([@dmw039C34]; [@dmw039C75]; [@dmw039C90]).

GDF8 and ovarian steroidogenesis {#dmw039s11a}
--------------------------------

In chicken embryos, GDF8 is extensively expressed in various tissues, including the gonads (testis and ovary) ([@dmw039C103]). In bovine ovaries, microarray analysis revealed the expression of *GDF8* in the GCs of different sizes of antral follicles ([@dmw039C171]). Our most recent immunohistochemistry analysis revealed that GDF8 and its putative functional receptors (ACVR2A, ACVR2B and ALK5) are expressed in the GCs of growing follicles in the human ovary (unpublished data). Moreover, the mature GDF8 protein is detectable in the follicular fluid obtained from IVF patients ([@dmw039C30]). In addition, recent studies have identified a novel role for GDF8 in the regulation of human GC steroidogenesis. Specifically, GDF8 regulates steroid production by increasing aromatase/estradiol production while decreasing StAR/progesterone production in primary hGL cells ([@dmw039C31]). Analysis of the data from clinical samples supports these findings, as there is a negative correlation between GDF8 concentrations and progesterone concentrations in the serum and follicular fluid ([@dmw039C55], [@dmw039C57]). Moreover, GDF8 may enhance the FSH-induced aromatase/estradiol production, whereas GDF8 suppresses the LH-induced StAR/progesterone production in hGL cells ([@dmw039C31]). In this regard, GDF8 exerts a regulatory function by modulating GC responsiveness to gonadotrophins. Notably, GDF8 enhances GC responsiveness to FSH by up-regulating FSH receptor (FSHR) expression while suppressing GC responsiveness to LH by down-regulating LHR expression ([@dmw039C31]). In line with these results, our previous studies showed that activins (activin A, B and AB) may act in a similar manner to modulate steroidogenesis in the same cell model ([@dmw039C26]). The downstream signaling pathway may account for the similar cellular effects, as both GDF8 and activins act through SMAD2/3-SMAD4-mediated target gene regulation in human GCs ([@dmw039C55]; [@dmw039C23]).

GDF8 and GC proliferation {#dmw039s11b}
-------------------------

During follicular development, GC proliferation and GC terminal differentiation are the key processes essential for oocyte maturation, ovulation and luteinization ([@dmw039C10]). At the periovulatory stage, various regulatory endocrine and paracrine factors meticulously modulate the functional switch of GCs from a highly proliferative status to a non-proliferative, terminally differentiated status ([@dmw039C122]). Beyond its role in regulating steroid production, an *in vitro* study showed that GDF8 suppresses human GC proliferation ([@dmw039C33]). This negative regulatory effect is mediated by another growth factor, connective tissue growth factor (CTGF), indicating that GDF8 and CTGF may be involved in the control of highly proliferative and non-proliferative events during human follicular development ([@dmw039C33]).

GDF8 and extracellular matrix formation {#dmw039s11c}
---------------------------------------

Lysyl oxidase (LOX) is the key enzyme for the final assembly and stabilization of the extracellular matrix that is essential for follicle and oocyte maturation ([@dmw039C94]; [@dmw039C200]). In the rat ovary, the LOX expression level is positively correlated with oocyte quality ([@dmw039C92]). In many organs, CTGF is a principle mediator of extracellular matrix-related tissue remodeling ([@dmw039C111]). Both CTGF and LOX are expressed in human GCs, and CTGF mediates the GDF8-induced increase in LOX activity and LOX protein expression ([@dmw039C32]). Interestingly, the GDF8-induced up-regulation of *CTGF* expression in human GCs occurs through the ALK5-mediated SMAD2/3-SMAD4 signaling pathway ([@dmw039C32]). This finding is inconsistent with a previous study demonstrating that GDF8 signaling is mainly dependent on ALK4, but not ALK5, in mouse C2C12 myoblasts, indicating that the type I receptor-mediated GDF8 downstream signaling is cell-type specific ([@dmw039C96]). Specifically, GDF8 acts through ALK4 in myoblast cells, while ALK5 mediates the GDF8-induced cellular action in non-myogenic cells.

GDF8 and COC expansion {#dmw039s11d}
----------------------

The occurrence of COC and the extent of cumulus expansion have been linked to oocyte competence and are potentially useful as indicators for oocyte selection in the IVF program ([@dmw039C11]; [@dmw039C60]). The combined results of the *in vitro* studies and the clinical data also revealed a positive correlation between *PTX3* expression levels in cumulus cells and their corresponding oocyte quality and subsequent fertilization rates ([@dmw039C212]; [@dmw039C86]). Consistent with the effects of BMP4 and BMP7, GDF8 might modulate cumulus expansion by down-regulating the key linking protein, PTX3, in human GCs ([@dmw039C30]).

Taken together, GDF8 is expressed in human GCs, and its mature proteins are detectable in follicular fluid. A series of functional studies have demonstrated the roles of GDF8 in regulating steroidogenesis, gonadotrophin responsiveness, cell proliferation, *LOX* expression, LOX activity and *PTX3* expression in human GCs (Fig. [3](#dmw039F3){ref-type="fig"}). These findings suggest that this unique TGF-β superfamily member might play a critical role in modulation of the final differentiation processes in the growing follicles, most likely by acting as both a maturation stimulator and a luteinization inhibitor. Figure 3Schematic diagram summarizing potential roles of GDF8 in a human growing follicle. In this follicular microenvironment, the locally produced GDF8 may promote aromatase/estradiol and FSHR expression, suppress StAR/progesterone and LHR expression and down-regulate PTX3 expression. In addition, GDF8 induces the expression of CTGF, which contributes to the suppression of GC proliferation and the increase in LOX activity. 3βHSD, 3β-hydroxysteroid dehydrogenase; CTGF, connective tissue growth factor; ECM, extracellular matrix; LOX, lysyl oxidase; P450scc, P450 side-chain cleavage enzyme; PTX3, pentraxin 3; FSHR, FSH receptor; LHR, LH receptor.

Perspectives and therapeutic potential {#dmw039s12}
======================================

A more comprehensive understanding of the physiological roles of BMPs/GDFs in the human ovary will provide significant insights into ovarian pathology and lead to new methods of approaching fertility regulation, whether the goal is to develop alternative forms of contraception, to diagnose and treat human infertility, or to develop safer and reliable protocols of inducing ovulation in ART. The involvement of BMP/GDF signaling pathways in a wide range of developmental and pathophysiological processes of reproductive biology makes targeting these pathways a potential therapeutic approach to overcome female infertility. At present, several recombinant human BMPs/GDFs and their inhibitors or antagonists have undergone clinical trials or have received US Food and Drug Administration (FDA) approval in human skeletal and muscular systems ([@dmw039C65]; [@dmw039C99]; [@dmw039C112]; [@dmw039C172]; [@dmw039C106]; [@dmw039C159]). Furthermore, the latest development of gene therapy and BMP-ligand trapping approaches are currently attracting more attention ([@dmw039C99]; [@dmw039C78]; [@dmw039C162]; [@dmw039C173]). All of the above information clearly reflects the availability of potential new medications acting on the BMP/GDF pathways for the treatment of a variety of human diseases, including female reproductive pathologies. However, further human clinical trials are warranted to investigate the efficacy, safety and administration routes of these pharmaceutical applications.

Conclusion {#dmw039s13}
==========

In the last decade, research regarding locally produced growth factors and intra-follicular signaling between the oocyte and the follicle cells has been of considerable interest. The accumulated data indicate that the intra-ovarian BMP/GDF system is of great importance in controlling female reproduction, including PGC development, cell--cell communication, steroidogenesis, COC formation and expansion, oocyte maturation, ovulation and luteolysis. Thus, the relationship between the oocyte and its supporting cells (GCs and theca/stroma cells) should be regarded as a synchronous partnership. During follicular development, all of these cell types play essential, yet sometimes distinct, roles in regulating ovarian functions to generate a competent oocyte for embryo development. A comprehensive understanding of the expression, actions and underlying molecular mechanisms of the BMP/GDF system in the human ovary is critical to the development of clinical approaches (diagnosis and/or treatment) for women suffering from infertility and ovulation dysfunction.
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[^1]: ACVR, activin receptor; ALK, activin receptor-like kinase; BMP, bone morphogenetic protein; BMPR, bone morphogenetic protein receptor; GDF, growth differentiation factor; SMAD, Sma- and Mad-related protein.

[^2]: GC, granulosa cell; ND, Not documented.

[^3]: BMR, bone morphogenetic proteins; GDF, growth differentiation factors; CL, corpora lutea; ELISA, enzyme-linked immunosorbent assay; FF, follicular fluid; IHC, immunohistochemistry; RT-qPCR, quantitative real-time PCR.

[^4]: ^a^Expressed only in fetal ovary.
